Addressing Cognitive and Psychiatric Effects of Antiepileptic Drugs

Slides:

Advertisements

Similar presentations

Antiepileptic Drugs and Suicidality: Background Evelyn Mentari, M.D., M.S. Clinical Safety Reviewer Division of Neurology Products/CDER Food and Drug Administration.

Advertisements

Suicidality and Anti-epileptic Drugs: Status of Clinical Trial Data Analysis Evelyn Mentari, MD, MS Division of Neurology Products.

Accutane-Psychiatric Disorders A Pharmacoepidemiological Safety Assessment Robert C. Nelson, PhD RCN Associates, Inc. Annapolis, MD.

Psychological Aspects of Epilepsy Kami Marchese, Psy.D.

Dr Seddigh Psychiatric Aspects of Epilepsy1 By : Dr Seddigh HUMS.

+ Module Four: Patient/Family Education and Self-Management At the end of this module, the participant will be able to: Describe three learning needs of.

1 IRIS Initiative to Reduce the Impact of Schizophrenia DON’T DELAY! IT’S TIME TO REDUCE THE IMPACT OF PSYCHOSIS IN YOUNG PEOPLE……. NOW!

SMOKING in ADOLESCENTS with PSYCHIATRIC or ADDICTIVE DISORDERS.

Brain diseases: Substance abuse and co-occurring disorders Mark Publicker, MD FASAM.

Cognitive and behavioral endpoints as primary outcome variables in epilepsy clinical trials David W. Loring, Ph.D. Department of Neurology Emory University.

ALLIE PUNKE PHARMACOKINETICS: ANTIEPILEPTIC DRUGS.

© 2016 Direct One Communications, Inc. All rights reserved. 1 Recent Research Expands Our Understanding of Perampanel Christian M. Cabrera Kang, MD Emory.

Journal Club Neuropsychological effects of levetiracetam and carbamazepine in children with focal epilepsy. Rebecca Luke 2/9/2016.

Switching to Generic Antiepileptic Drugs (AEDs)

Ozeraitiene V1, Varvuolyte S1,2, Makaraviciene D3, Stasinskaja N4,

Recognize and treat depression in epilepsy Maryam PoursadeghFard Shiraz University of Medical Science (1)Introduction: Depression is a major problem.

Antidepressant-Induced Sexual Dysfunction

Statin Myopathy (AHA/ACC/NHLBI)

Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.

RESISTANT HYPERTENSION OR POOR PATIENT ADHERENCE? TIPS TO GAIN CONTROL

Access to NOAC Therapy:

To Titrate or Not: Optimizing Treatment With Antiepileptic Drugs

Modern Strategies for Basal Insulin Use in T2D

Epilepsy Treatment Across the Spectrum

Optimizing Quality of Life and Mental Health in Patients With Psoriasis.

Differentiating Drug-Seeking Behavior From Poorly Controlled Pain

Staying on Course: Optimizing Antiepileptic Medication Regimens

Case Challenges in Chronic Migraine

Definitions: Seizure, Epilepsy, Epilepsy Syndrome

Update on NSAID Use:.

Introduction. Risk Communication With Patients: Your Guide to Resources and Recommendations.

Management Considerations in Epilepsy Among Long-Term Care Residents

Beyond the Basics: What You Need to Know About Treating Insomnia

Addressing Iron Deficiency in Chronic HF

Diagnosis and Management of Narcolepsy in Psychiatry:

Transition of Care in Epilepsy Among Patients Entering Long-Term Care

Oral Anticoagulants in AFa,b A Brief History.

The Mood Disorder Spectrum

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

Treatment of Generalized Tonic-Clonic Seizures in the Modern Era

Introduction. A Reality Check on BP Goals and Optimizing Patient Adherence to Treatment.

Seizures in the Elderly: Treatment and Special Considerations

Management of Adolescents With Seizures

Access to NOAC Therapy:

A Journal Club on Lipid Management:

Understanding PAD.

Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA

Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.

Expert Debate in MDD.

The Importance of Getting the Dose Right in HF

Atrial Fibrillation.

Program Overview. Major Depressive Disorder: The Challenging Patient and the Goal of Recovery.

PrEP Ongoing Care.

CAD/PAD in Primary Care

Cancer-Associated Thrombosis

Expert Perspectives in the Recognition and Management of Lennox-Gastaut Syndrome.

Critical Decision Points in Insomnia

Communicating With Your Patients About Major Depressive Disorder

How to Optimize Cholesterol Management in High-Risk CV Patients

Incorporating Prostacyclins Into Practice

Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA

Treating Atypical Hemolytic Uremic Syndrome A Case Discussion

Issues in Patients With Severe Epilepsy

Life-Threatening Chemotoxicity

Rational Pharmacotherapy Selection for Insomnia

Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.

Empowering Patients and Prescribers to Improve Treatment Adherence in Schizophrenia.

Widening the Options for Major Depressive Disorder

Fresh perspectives ON BASAL Insulins in diabetes care

The Challenge of Insulin Titration

Presentation transcript:

Addressing Cognitive and Psychiatric Effects of Antiepileptic Drugs

Program Goals

Lifetime Prevalence of Psychiatric Comorbidities in Epilepsy

Mechanisms Operant in the Development of Psychiatric Iatrogenic Symptomatology

AEDs With Psychotropic Properties

Pathogenic Mechanisms for AED-Induced Depression

Psychiatric Adverse Effects in Patients With Epilepsy Treated With Topiramate

Effect of Co-occurrence of Depression With Other Histories During Rapid Topiramate Titration

Discontinuation of Levetiracetam Related to Psychiatric Adverse Effects

Dose of Levetiracetam and Psychiatric Adverse Effects

AEDs and Suicidality FDA Conclusions From Meta-Analysis

FDA Meta-Analysis Suicidal Behavior or Ideation Stratified by AED

FDA Meta-Analysis Methodological Concerns

Antiepileptic Drugs and Suicidality Expert Consensus Statement

Risk Factors for Suicidality in Epilepsy

Can Iatrogenic Psychiatric Symptoms/Effects Be Prevented?

Iatrogenic Cognitive Effects of AEDs Basic Concepts

Cognitive Abilities Affected by AEDs

First-Generation AEDs Cognitive Effects in Healthy Adults

Second-Generation AEDs Cognitive Effects in Healthy Adults

Newer AEDs vs Other AEDs In Healthy Volunteers

Delayed Recall in Healthy Volunteers

Third-Generation AEDs Iatrogenic Cognitive Effects

AEDs With Specific Iatrogenic Cognitive Deficits

Prevention of Iatrogenic Cognitive Adverse Effects

Summary

Abbreviations

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)